ReviewCureus2025
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced endometrial cancer (aEC) presents a formidable therapeutic challenge, particularly in patients with recurrent or metastatic disease. Historically, platinum-based chemotherapy is the mainstay treatment for aEC. However, the treatment paradigm has shifted with the emergence of immune checkpoint inhibitors (ICIs) and targeted therapies. Lenvatinib combined with pembrolizumab (LVB + PMB) has emerged as a promising regimen, particularly for patients with proficient mismatch repair (pMMR) tumors who typically respond poorly to ICI monotherapy. This review synthesizes recent data comparing LVB + PMB to chemotherapy, focusing on efficacy, safety, and molecular subtype-guided treatment selection. Findings from the KEYNOTE-775 and LEAP-001 trials are highlighted. We also delve into the molecular and immunologic landscape of aEC, providing a mechanistic rationale for treatment response and resistance. While LVB + PMB shows superior progression-free survival in second-line settings, its first-line application in unselected populations remains inconclusive. Therefore, strategic patient stratification and biomarker development remain key to maximizing clinical outcomes. Furthermore, we discuss the clinical implications of these findings, explore future research directions, including novel combinations and biomarkers, and provide recommendations for the evolving therapeutic landscape.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.